August 1, 2024 Advancing Rare Disease Measurement With The Rare Disease COA Resource It is estimated that more than 350 million people worldwide live with a rare disease.
April 24, 2024 COA Program Concludes Successful Annual Meeting On April 17 and 18, C-Path's Clinical Outcome Assessment (COA) Program hosted its Annual Meeting in Rockville, MD...
May 18, 2018 “Improving Clinical Trials to Deliver Better Treatments,” as featured in the Spring 2018 edition of “Progress, the research magazine of Parkinson’s UK”
May 7, 2018 C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
December 18, 2017 C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS) Tucson, AZ – December 18, 2017 Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
October 24, 2017 US FDA Awards I-ACT for Children a Grant for Pediatric Medicines and Devices Network
August 17, 2017 National MS Society-Supported Collaborators Publish Reviews of Tools Used to Measure MS Progression
August 17, 2017 The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
